National Health (Immunisation Program Designated Vaccines) Variation Determination 2015 (No. 2) (Cth)
National Health (Immunisation Program – Designated Vaccines) Variation Determination 2015 (No. 2)[1]
National Health Act 1953
I, Kirsty Faichney, delegate of the Minister for Health, make this Determination under subsections 9B (2) and (5) of the National Health Act 1953.
Dated 26 October 2015
Ms Kirsty L Faichney
Assistant Secretary
Immunisation Branch
Office of Health Protection
Department of Health
Name of Determination
This Determination is the National Health (Immunisation Program – Designated Vaccines) Variation Determination 2015 (No. 2).
Commencement
Schedule 1, Items 4 and 7 of this Determination commence on 31 October 2015.
Schedule 1, Items 1, 2, 5 and 6 of this Determination commence on 1 November 2015.
Schedule 1, Item 3 of this Determination commences on 1 January 2016.
Variation of National Health (Immunisation Program – Designated Vaccines) Determination 2014 (No. 1)
Schedule 1 varies the National Health (Immunisation Program – Designated Vaccines) Determination 2014 (No. 1).
Schedule 1 Amendments
(section 3)
[1] Section 7
insert after subsection 7(7):
(8) For item 207A of Schedule 1, a designated vaccine mentioned in that item may be provided to:
(a) a person who is at least 65 years; or
(b) an Aboriginal and/or Torres Strait Islander person who is:
(i) aged at least 3 years but less than 5 years; or
(ii) 15 years or older; or
(c) a person who is at least 3 years
(i) who:
(A) has cardiac disease including cyanotic congenital heart disease, coronary artery disease and congestive heart failure; or
(B) has a chronic respiratory condition including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema and severe asthma; or
(C) has another chronic illness requiring regular medical follow-up or hospitalisation in the preceding year, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies and impaired immunity (including drug-induced immune impairment); or
(D) has a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders; or
(E) has impaired immunity, including HIV infection; or
(F) is receiving long-term aspirin therapy; or
(G) is pregnant.
[2] Section 7
insert after subsection 7(8):
(9) For item 208A of Schedule 1, a designated vaccine mentioned in that item may be provided to:
(a) an Aboriginal and/or Torres Strait Islander person who is:
(i) aged at least 6 months but less than 3 years; or
(b) a person who is at least 6 months but less than 3 years
(i) who:
(A) has cardiac disease including cyanotic congenital heart disease, coronary artery disease and congestive heart failure; or
(B) has a chronic respiratory condition including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema and severe asthma; or
(C) has another chronic illness requiring regular medical follow-up or hospitalisation in the preceding year, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies and impaired immunity (including drug-induced immune impairment); or
(D) has a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders; or
(E) has impaired immunity, including HIV infection; or
(F) is receiving long-term aspirin therapy.
[3] Section 7
insert after subsection 7(9):
(10) For an item in Schedule 1 that specifies circumstances in which a designated vaccine may be provided to a child that include the specification of an age not more than 4 years, the vaccine may be provided to a child if:
(a) the child did not receive the vaccine at the age specified in the item; and
(b) the child is less than 10 years of age.
Note: For example, if a vaccine is intended to be provided for the immunisation of a child at 2 months, 4 months and 6 months of age but the child does not receive the vaccine at those ages, the doses of vaccine may be provided at any time before the child’s 10th birthday.
[4] Schedule 1, Part 1
insert after Item 102A:
| 102B | Vaccine Diphtheria, tetanus and pertussis (child) Circumstances Vaccine may be provided to a child who is about 18 months of age. | Tripacel | Injection (0.5mL) | Each of the following: (a) diphtheria toxoid — not less than 30 IU; (b) tetanus toxoid — not less than 40 IU; (c) PT — 10 µg; (d) FHA — 5 µg; (e) PRN — 3 µg (f) FIM 2+3 — 5 µg | 1 dose (booster) |
[5] Schedule 1, Part 2
insert after Item 207:
| 207A | Vaccine Influenza Circumstances Vaccine may be provided in the circumstances set out in subsection 7(8) | Fluarix Tetra | Injection (0.5mL) | For children 3 years and older but less than 9 years, 2 doses at least 1 month apart for the first vaccination and 1 dose per calendar year after that. For persons 9 years and above, 1 dose per calendar year. |
[6] Schedule 1, Part 2
insert after Item 208:
| 208A | Vaccine Influenza Circumstances Vaccine may be provided in the circumstances set out in subsection 7(9) | FluQuadri Junior | Injection (0.25mL) | For children 6 months and older but less than 3 years, 2 doses at least 1 month apart for the first vaccination and 1 dose per calendar year after that. |
[7] Schedule 1, Part 3
insert after Item 305:
| 305A | Vaccine Diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Haemophilus influenzae type b (Hib) Circumstances Vaccine may be provided to a child who is about 2, 4 or 6 months old. | Hexaxim | Injection (0.5mL) | Each of the following: (a) diphtheria toxoid — not less than 20 IU; (b) tetanus toxoid — not less than 40 IU; (c) PT — 25 µg; (d) FHA — 25 µg; (e) inactivated poliovirus type 1 (Mahoney) — 40 D‑antigen units; (f) inactivated poliovirus type 2 (MEF‑1) — 8 D‑antigen units; (g) inactivated poliovirus type 3 (Saukett) — 32 D‑antigen units; (h) recombinant hepatitis B surface antigen — 10 µg; (i) Hib polysaccharide (Polyribosylribitol Phosphate) — 12 µg (j) Hib polysaccharide conjugated to tetanus protein — 22-36 µg | 3 doses |
[1]Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See
0
0
0